Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
redalsomatropin alfa
- Development stage
- Unknown
- Lead developer
- JCR Pharmaceuticals
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
Redalsomatropin alfa (JR-142) is a recombinant long-acting growth hormone developed by JCR Pharmaceuticals for the treatment of pediatric growth hormone deficiency. Utilizing proprietary half-life extension technology, JR-142 is designed to allow once-weekly subcutaneous administration, addressing the inconvenience and discomfort associated with current daily or near-daily growth hormone replacement therapies. The drug primarily targets the growth hormone receptor (GHR), stimulating linear growth in children with insufficient endogenous growth hormone production. Phase III clinical trials are underway in Japan to evaluate its efficacy and safety compared to standard daily therapy, focusing on outcomes such as height velocity and insulin-like growth factor 1 (IGF-1) levels[1][2][4][7].
- Other names
- redalsomatropin alfaJR-142JR142JR 142
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on redalsomatropin alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on redalsomatropin alfa.